In clinical trials of potential new therapies for Central Nervous System (CNS) disorders, it can be challenging for site-based clinicians to reliably collect symptomatology data. Patient reported outcomes can often be incomplete and symptoms don’t always present in face-to-face clinical visits. This can lead to studies that take longer to produce conclusive efficacy data while also requiring a lot of hands-on support from site teams.In clinical trials of potential new therapies for Central Nervous System (CNS) disorders, it can be challenging for site-based clinicians to reliably collect symptom.
In clinical trials of potential new therapies for Central Nervous System (CNS) disorders, it can be challenging for site-based clinicians to reliably collect symptomatology data. Patient reported outcomes can often be incomplete and symptoms don’t always present in face-to-face clinical visits. This can lead to studies that take longer to produce conclusive efficacy data while also requiring a lot of hands-on support from site teams.